Dawson James downgraded ProPhase from Buy to Neutral
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/14/2022 | $12.00 → $15.00 | Buy | HC Wainwright & Co. |
| 12/20/2021 | $12.00 | Buy | HC Wainwright & Co. |
| 10/13/2021 | Buy → Neutral | Dawson James |
HC Wainwright & Co. reiterated coverage of ProPhase Labs with a rating of Buy and set a new price target of $15.00 from $12.00 previously
HC Wainwright & Co. initiated coverage of ProPhase Labs with a rating of Buy and set a new price target of $12.00
Dawson James downgraded ProPhase from Buy to Neutral
8-K - ProPhase Labs, Inc. (0000868278) (Filer)
DEFA14A - ProPhase Labs, Inc. (0000868278) (Filer)
8-K - ProPhase Labs, Inc. (0000868278) (Filer)
4 - ProPhase Labs, Inc. (0000868278) (Issuer)
3 - ProPhase Labs, Inc. (0000868278) (Issuer)
4 - ProPhase Labs, Inc. (0000868278) (Issuer)
Company cancels the Equity Line of Credit (ELOC) UNIONDALE, NY, Sept. 03, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ:PRPH), (the "Company" or "ProPhase"), a next generation biotech, genomics and consumer products company, announced today that they will be participating in Renmark Financial Communications Inc's live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Thursday, September 4, 2025, at 12:00 pm EDT. ProPhase Labs Inc. welcomes stakeholders, investors and other individual followers to register and attend this live event. The presentation will feature Ted Karkus, Chairman and Chief Executive Officer. Topics to be covered will include a gener
UNIONDALE, NY, Aug. 19, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) (the "Company" or "ProPhase"), a next generation biotech, genomics and consumer products company, today announced that it filed a definitive proxy statement ("DEF 14A") with the U.S. Securities and Exchange Commission ("SEC") on Friday, August 15, 2025 and received a "no further comments" letter from the SEC's Division of Corporation Finance Office of Life Sciences, indicating that the Staff had completed the review of the Preliminary Proxy Statement of Schedule 14A, on Monday, August 18, 2025. The Special Meeting of Shareholders that was scheduled for August 29, 2025 will now be held on Tuesday, September
Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Aug. 14, 2025 /PRNewswire/ -- Equity Insider News Commentary – Despite alarming federal budget cuts that stand to potentially harm the national battle against cancer, it appears that the private sector continues to step up, with hundreds of millions of VC dollars pouring into oncology ventures so far in 2025. While there has been a recent victory in the Senate to restore $15 million for the Pancreatic Cancer Research Program (PCARP), the prior elimination of the only federal program dedicated solely to researching pancreatic cancer served as a stark reminder of these ongoing funding challenges. This dyn
SC 13D/A - ProPhase Labs, Inc. (0000868278) (Subject)
SC 13D/A - ProPhase Labs, Inc. (0000868278) (Subject)
SC 13D/A - ProPhase Labs, Inc. (0000868278) (Subject)
ProPhase Delivers Significant Operational and Financial Improvements, Advances Multiple Non-Dilutive Liquidity Initiatives, and Targets Transformational Growth Catalysts Company granted key U.S. patent on BE-Smart™ Esophageal Adenocarcinoma Risk Assessment test (August 2025) Company to hold a virtual conference call Wednesday, August 13, 2025, at 2:00 PM ET UNIONDALE, NY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH), (the "Company" or "ProPhase") a diversified diagnostics, genomics, and consumer healthcare company, today reported financial and operational results for the three and six months ended June 30, 2025. Ted Karkus, CEO of ProPhase Labs, will present to s
UNIONDALE, NY, Aug. 11, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ:PRPH), (the "Company" or "ProPhase"), a next generation biotech, genomics and consumer products company, announced today that they will be presenting second quarter 2025 financial results on a virtual conference call hosted by Renmark Financial on August 13, 2025, at 2:00 pm EDT. A press release detailing these results will be issued prior to the virtual conference call. ProPhase Labs Inc. welcomes stakeholders, investors, and other individual followers to register and attend this live event. Investors interested in participating in this live event will need to register using the link below. After the event, a re
Highlights Multiple Significant Potential Liquidity Events Anticipated Within the Next Few Months Completes Significant Reductions in Overhead and Expenses BE-Smart Esophageal Cancer Test Study has been Submitted in the Journal of Clinical Gastrointestinal Hepatology Company to hold a virtual conference call Tuesday, May 20, 2025, at 10:00 AM ET GARDEN CITY, NY, May 20, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ:PRPH), (the "Company" or "ProPhase") a next generation biotech, genomics and consumer products company, today reported its financial and operational results for Q1 ended March 31, 2025, and outlined significant strategic corporate developments. Ted Karkus, CEO of ProP
USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 18, 2025 /PRNewswire/ -- USA News Group News Commentary – According to a recent report in Newsweek, more Americans younger than 50 are getting cancer. In fact, the report cites a recent study from the National Institutes of Health (NIH), which found that between 2010 and 2019, more than 2 million Americans aged 15 to 49 were diagnosed with cancer, with early-onset cases rising significantly in 14 different cancer types, including breast, colorectal, and kidney cancers. The dire statistics from the study come at a time where Bloomberg has recently reported on the skyrocketing costs of cancer drugs,
GARDEN CITY, NY, Feb. 18, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) ("ProPhase" or the "Company"), a next-generation biotech, genomics, and consumer products company, today announced the appointment of Stu Hollenshead as Chief Operating Officer, marking a pivotal step in the company's expansion into consumer-centered health and wellness products. As COO, Hollenshead will focus on accelerating ProPhase Labs' consumer-facing strategy, leveraging his deep expertise in direct-to-consumer growth, subscription models, digital marketing, and audience monetization to position the company as a leader in science-backed health solutions. The Company plans to provide additional updat
Leveraging ProPhase Labs' AI platform, massive genomics database and patented esophageal cancer insights for Antibody Drug Conjugates development. Garden City, NY, April 16, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) ("ProPhase" or the "Company"), a biopharma, genomics, and diagnostics Company, today announced an innovative step forward in cancer treatment research with the introduction of Project ZenQ-AI. This project employs the Company's state-of-the-art AI platform which was meticulously developed with leading AI technology platforms and systems. The Company is harnessing its extensive genomic database—built over the last six years from whole genome sequencing tests (W